SUMMARY A longitudinal study of 44 haemophilic children, all in a treatment programme with factor concentrates, was undertaken to evaluate the occurrence, characteristics, and evolution of hepatitis B virus (HBV) 
Post-transfusion hepatitis is a well known complication of treatment with blood derivatives in patients with coagulation disorders, -3 and hepatitis B virus (HBV) infection, with a possible associated liver disease, has often been investigated in such patients.2 4 5 According to previous reports>S about 90% of haemophilic patients show signs of HBV infection during replacement therapy, and a history of symptomatic acute hepatitis is rarely present; in a small number there is an evolution to chronicity, with liver disease ranging from chronic persistent hepatitis to active cirrhosis.69 Up to now this subject has been rarely studied in haemophilic children,9 even though this group offers an excellent opportunity for a thorough analysis, incJuding the amount of exposure to clotting concentrates before infection, the age at which infection occurs, the possibility ofdeveloping chronic hepatitis B surface antigenaemia and chronic liver disease, seroconversion (how many and after how long), and the eventual superinfection with agent. In short, children offer a unique group for assessing the natural course and long term evolution of HBV infection. Therefore, we have undertaken a longitudinal study of 44 haemophilic children, all in a treatment programme with commercial factor concentrates, to evaluate the occurrence, characteristics, and evolution of HBV infection.
Patients and methods
Forty four children (36 with haemophilia A, four with haemophilia B, and four with von Willebrand's disease) have been followed and tested at three to six month intervals since 1979 for hepatitis B surface (HBsAg) 
Results
Details about the evolution of serological signs of HBV infection throughout the follow up are presented in Table 1 . As a whole, 24 children (55%) (group I) developed infection, while 20 (group II) did not. The main characteristics of treatment in the two groups are summarised in Table 2 . None of the variables examined (age at onset of treatment, number of infusions given, and total amount of concentrate received) showed significant differences between children with and without infection (p> 0-05).
HBV infection (onset and evolution). In group I the mean age of infection with HBV was 5 years 4 months (range 2 years 3 months to 12 years 2 months). In 16 children the infection was detected by the presence of HBsAg. In six cases it was already present at the beginning of the study (with a history of acute hepatitis in three patients). In six patients the infection occurred during the first year, Besides, the use of factor VIII and IX concentrates, which are easy to handle, has permitted home infusion programmes and has resulted in a great improvement in the quality of life of haemophiliacs. 13 As HBV infection is usually acquired during the first years of treatment most reports about adult haemophiliacs show a high prevalence of signs of past infection but cannot describe the characteristics and evolution of acute infection. Children do offer this opportunity. Our data show a high prevalence of HBV infection (55%) in a paediatric group of haemophilic patients exposed early to treatment with concentrate. Comparable data about prevalence of infection (ranging from 44%4 to 63% 14) have been previously described in paediatric groups; to account for a much higher reported percentage (85%)5 the authors themselves' suggested that this group.bmj.com on November 8, 2017 -Published by http://adc.bmj.com/ Downloaded from group might have been exposed to treatment with concentrate before the HBsAg screening of plasma donors by sensitive tests. The higher prevalence of detectable HBsAg (present in 36% of the patients) in our group compared with other studies9 1o might be the result of frequent screening done in our children, detecting even short lived antigenaemia. The patients described by Spero et a19 were older (up to 21 years) and it was likely that a high percentage had already seroconverted from HBsAg to anti-HBs. Furthermore, this might also account for the lower prevalence of HBsAg in haemophilic adult patients.3 4 A peculiar feature of our group was the very high incidence of chronic HBV infection, as nine out of 24 infected children (38%) showed this behaviour. This high percentage seems to be halfway between the behaviour of normal children and of immunosuppressed ones, as in these two categories the rate of chronic evolution was reported to be 9% and 69%, respectively. 15 Multiple transfusions, with a continuous antigenic stimulation, could possibly lead to a derangement of the immune system and partially account for the impaired clearance of HBsAg in these patients.
As regards the age of infected children, Spero et al reported HBsAg chronicity in four out of seven haemophilic children who had been exposed to factor concentrates before 5 years of age compared with five out of 65 patients treated after 5 years of age.9 It was suggested then that the age of first exposure to factor concentrates might.be an important element in the development of chronic liver disease and of chronic HBsAg carrier state. In our experience, however, the age of infection would seem to be a more important factor than the age of first exposure for predicting a chronic evolution: in fact, seven out of the 12 children infected before 5 years developed chronic HBV infection compared with two out of 12 patients infected after this age. The age at first exposure per se is not important, as all but two infected children had been first exposed to treatment with factor concentrate before 5 years; besides, no significant difference could be found in the age of first exposure between children with and without infection.
Haemophilic children seem to behave like nonhaemophilic ones, as it is known that the probability that HBV infection will lead to the carrier state is inversely related to the age of infection, and the risk of an infected child becoming a carrier drops rapidly during the first years of life.16 and severe liver disease we have described out of nine with chronic infection would confirm a poor prognosis in the presence of this coinfection; as four other children without ongoing 6 infection showed rather severe liver disease, however, more data, with an accurate histologic diagnosis, are necessary to confirm this hypothesis and to assess the respective pathogenic roles of HBV and the 6 agent.
Finally, in our experience, as in another,' no evidence of neoplastic transformation was found; as the association, however, between HBV infection and hepatoma has already been reported in the paediatric age, 18 a careful follow up of HBsAg positive patients is still mandatory. To prevent HBV infection (and an eventual 6 superinfection) active immunisation against HBV seems to be the easiest solution at present. Besides, to reduce both hepatitis B and non-A non-B hepatitis, treatment with hepatitis free clotting factor concentrates19 and the use (when possible) of volunteer donor cryoprecipitates are feasible choices.
The production of human factor VIII by recombinant DNA techniques should definitely solve the problem in the future.20
